Last reviewed · How we verify
BXCL501 80 Micrograms — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BXCL501 80 Micrograms (BXCL501 80 Micrograms) — BioXcel Therapeutics Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BXCL501 80 Micrograms TARGET | BXCL501 80 Micrograms | BioXcel Therapeutics Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BXCL501 80 Micrograms CI watch — RSS
- BXCL501 80 Micrograms CI watch — Atom
- BXCL501 80 Micrograms CI watch — JSON
- BXCL501 80 Micrograms alone — RSS
Cite this brief
Drug Landscape (2026). BXCL501 80 Micrograms — Competitive Intelligence Brief. https://druglandscape.com/ci/bxcl501-80-micrograms. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab